CXCL5/ENA-78 Antibody (33160) [Alexa Fluor® 594]

• Reactivity: Hu
• Applications: WB, IHC, B/N
• Clone: 33160
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 594

CXCL5/ENA-78 Antibody (33160) [Alexa Fluor® 594] Summary

• Immunogen: E. coli-derived recombinant human CXCL5/ENA-78
  Ala37-Asn114 (predicted)
  Accession # P42830
• Specificity: Detects human CXCL5/ENA‑78 in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant human (rh) CXCL1, 2, 3, 8, 10, or recombinant mouse CXCL2 is observed.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry
  • Neutralization
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CXCL5/ENA-78 Antibody (33160) [Alexa Fluor® 594]

• chemokine (C-C motif) ligand 5
• C-X-C motif chemokine 5
• CXCL5
• CXCL5/ENA-78
• ENA78
• ENA-78
• ENA-78(1-78)
• Epithelial-derived neutrophil-activating protein 78
• Neutrophil-activating peptide ENA-78
• neutrophil-activating protein 78
• SCYB5ENA78

Background

CXCL5, also known as epithelial cell-derived-neutrophil-activating-peptide (ENA78), is an 8 kDa proinflammatory member of the CXC subfamily of chemokines. Its Glu-Leu-Arg (ELR) motif confers angiogenic properties and distinguishes it from ELR^- CXC chemokines which are angiostatic. Human CXCL5 shares 57% amino acid (aa) sequence identity with mouse and rat CXCL5. Among other human ELR⁺ chemokines, it shares 77% aa sequence identity with CXCL6/GCP2 and 35%‑51% with CXCL1/GRO alpha, CXCL2/GRO beta, CXCL3/GRO gamma, CXCL7/NAP2, and CXCL8/IL8. Inflammatory stimulation upregulates CXCL5 production in multiple hematopoietic cell types, fibroblasts, endothelial cells, and vascular smooth muscle cells. In vivo, CXCL5 is elevated at sites of inflammation and pulmonary fibrosis where it promotes neutrophil infiltration and activation as well as angiogenesis. Its upregulation contributes to increased vascularization, tumor growth, and metastasis in many cancers. Full length CXCL5 (78 aa) is trimmed at the N-terminal end by Cathepsin G and chymotrypsin to ENA74 (74 aa) and ENA70 (70 aa), with the shortened forms showing increased potency relative to full length CXCL5. CXCL5 exerts its effects primarily through interactions with CXCR2. It also binds DARC, a decoy chemokine receptor which can limit CXCR2-mediated responses.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.